News >

Durvalumab/Olaparib Regimen Reveals Promising pCR Probability Across High-Risk HER2- Breast Cancer

Jessica Hergert
Published: Friday, May 22, 2020

Lajos Pusztai, MD, DPhil, professor of medicine medical oncology and co-leader of Genetics, Genomics, and Epigenetics at Yale Cancer Center

Lajos Pusztai, MD, DPhil

The triplet regimen of durvalumab (Imfinzi), olaparib (Lynparza), and taxane-based chemotherapy demonstrated promising efficacy as neoadjuvant treatment in patients with early-stage, high-risk, HER2-negative stage II/III breast cancer in the phase 2 I-SPY 2 trial, explained Lajos Pusztai, MD, DPhil.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication